Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM.

Here's what investors need to know about the announcement.

Earnings

Adaptimmune Therapeutics beat estimated earnings by 80.0%, reporting an EPS of $-0.05 versus an estimate of $-0.25.

Revenue was up $2.44 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.17 which was followed by a 1.3% increase in the share price the next day.

Here's a look at Adaptimmune Therapeutics's past performance:

To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.